JP2022522650A5 - - Google Patents

Info

Publication number
JP2022522650A5
JP2022522650A5 JP2021548244A JP2021548244A JP2022522650A5 JP 2022522650 A5 JP2022522650 A5 JP 2022522650A5 JP 2021548244 A JP2021548244 A JP 2021548244A JP 2021548244 A JP2021548244 A JP 2021548244A JP 2022522650 A5 JP2022522650 A5 JP 2022522650A5
Authority
JP
Japan
Prior art keywords
crispr
activity
cas effector
polypeptide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021548244A
Other languages
English (en)
Japanese (ja)
Other versions
JP7649748B2 (ja
JP2022522650A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/021214 external-priority patent/WO2020181102A1/en
Publication of JP2022522650A publication Critical patent/JP2022522650A/ja
Publication of JP2022522650A5 publication Critical patent/JP2022522650A5/ja
Application granted granted Critical
Publication of JP7649748B2 publication Critical patent/JP7649748B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021548244A 2019-03-07 2020-03-05 Crispr-casエフェクターポリペプチド及びその使用方法 Active JP7649748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962815179P 2019-03-07 2019-03-07
US62/815,179 2019-03-07
PCT/US2020/021214 WO2020181102A1 (en) 2019-03-07 2020-03-05 Crispr-cas effector polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022522650A JP2022522650A (ja) 2022-04-20
JP2022522650A5 true JP2022522650A5 (enExample) 2023-03-13
JP7649748B2 JP7649748B2 (ja) 2025-03-21

Family

ID=72338076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548244A Active JP7649748B2 (ja) 2019-03-07 2020-03-05 Crispr-casエフェクターポリペプチド及びその使用方法

Country Status (5)

Country Link
US (1) US12312614B2 (enExample)
EP (1) EP3935155A4 (enExample)
JP (1) JP7649748B2 (enExample)
CN (1) CN114040971A (enExample)
WO (1) WO2020181102A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10660419B2 (en) * 2016-12-15 2020-05-26 Elc Management Llc Packaged skin treatment composition and method
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022256440A2 (en) 2021-06-01 2022-12-08 Arbor Biotechnologies, Inc. Gene editing systems comprising a crispr nuclease and uses thereof
WO2024006824A2 (en) * 2022-06-28 2024-01-04 Mammoth Biosciences, Inc. Effector proteins, compositions, systems and methods of use thereof
EP4622662A1 (en) 2022-11-23 2025-10-01 Amber Bio Inc. Gene-modifying endonucleases
CN120712355A (zh) 2023-02-15 2025-09-26 阿伯生物技术公司 用于抑制抑微管装配蛋白2(stmn2)转录物中的异常剪接的基因编辑方法
WO2025171210A1 (en) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions and methods for gene editing via homology-mediated end joining
WO2026015829A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Small reverse transcriptases and gene editing systems comprising such
WO2026015832A2 (en) 2024-07-12 2026-01-15 Arbor Biotechnologies, Inc. Reverse transcriptases and gene editing systems comprising such

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605709B1 (en) * 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7550263B2 (en) * 2003-09-05 2009-06-23 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
AU2011325956B2 (en) * 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2015089427A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crispr-cas systems and methods for altering expression of gene products, structural information and inducible modular cas enzymes
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN115216459B (zh) * 2015-12-29 2024-06-28 孟山都技术公司 新型crispr相关转座酶及其用途
US20200263190A1 (en) * 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
WO2018213351A1 (en) 2017-05-16 2018-11-22 The Regents Of The University Of California Thermostable rna-guided endonucleases and methods of use thereof
GB201712733D0 (en) * 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells

Similar Documents

Publication Publication Date Title
JP2017018125A5 (enExample)
JP7559005B2 (ja) 真核ゲノム修飾のための操作されたCas9システム
JP2023541400A5 (enExample)
JP2024083479A5 (enExample)
US20190382775A1 (en) Truncated crispr-cas proteins for dna targeting
JP2022526695A (ja) 遺伝子編集における非意図的な変異の阻害
JP2022519507A5 (enExample)
JP2023516226A5 (enExample)
JP2025102784A5 (enExample)
WO2022056254A3 (en) Dna modifying enzymes and active fragments and variants thereof and methods of use
JP7649748B2 (ja) Crispr-casエフェクターポリペプチド及びその使用方法
JP2023549339A5 (enExample)
CN110139927A (zh) Crispr-cas9抑制剂
CA2956224A1 (en) Cas9 proteins including ligand-dependent inteins
EP2855671A2 (en) New transcription activator-like effector (tale) fusion protein
AR125191A1 (es) Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
US20230242627A1 (en) Composition and method for activating latent human immunodeficiency virus (hiv)
WO2024198961A1 (zh) 一种Cas蛋白及其突变体、其相应的基因编辑系统及应用
JP2024543042A5 (enExample)
JP2024531607A5 (enExample)
WO2026011782A1 (zh) 抑制FXI基因表达的siRNA的制备方法
JP7249620B2 (ja) 核酸結合因子
US20060172373A1 (en) Mutant Recombinases
KR102935503B1 (ko) 신규 Cas12a 단백질, 신규 Cas12a 단백질의 변형체 및 이들의 진핵세포 유전체 편집 용도
JP2026515554A (ja) Crisprの干渉および活性化のための改善された方法および組成物